Axsome Therapeutics Executive Compensation (FY25)
AXSM · Executive and director compensation, fiscal 2025 only
The paid brief on Axsome Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 20, 2026Latest filing (8-K): June 9, 2026
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
222 figures on this page: 215 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
More on Axsome Therapeutics
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
Frequently asked questions
Answers drawn from the data on this page.
Who is Axsome Therapeutics' chief executive and what were they paid?
Herriot Tabuteau was paid $10,283,492 in total compensation as Chief Executive Officer, President, and Chairman of the Board for fiscal 2025.
What was Axsome Therapeutics' say-on-pay result?
The say-on-pay proposal drew 97.1% of votes cast including abstentions in favor at the meeting held June 5, 2026 for fiscal 2025.
Which companies are in Axsome Therapeutics' peer group?
The disclosed peer group names Alector, Inc., Allogene Therapeutics, Inc., Apellis Pharmaceuticals, Inc., BridgeBio Pharma, Inc. and Collegium Pharmaceutical, Inc., among others.
What is Axsome Therapeutics' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 23:1, against median employee compensation of $437,980.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Herriot Tabuteau Chief Executive Officer, President, and Chairman of the Board | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Mark Jacobson Chief Operating Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Nick Pizzie Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Hunter Murdock General Counsel | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Ari Maizel Chief Commercial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Ari Maizel | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Ari Maizel | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Ari Maizel | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Herriot Tabuteau | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Herriot Tabuteau | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Herriot Tabuteau | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Hunter Murdock | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Mark Jacobson | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Mark Jacobson | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Mark Jacobson | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Nick Pizzie | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Nick Pizzie | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Nick Pizzie | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Ari Maizel | Option | ◇ | — | ◇ | 2/21/2035 |
| Option | ◇ | — | ◇ | 2/27/2034 | |
| Option | ◇ | — | ◇ | 9/25/2033 | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Hunter Murdock | Option | ◇ | — | ◇ | 2/27/2034 |
| Option | ◇ | — | ◇ | 3/2/2033 | |
| Option | ◇ | — | ◇ | 3/4/2032 | |
| Option | ◇ | — | ◇ | 2/21/2035 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Nick Pizzie | Option | ◇ | — | ◇ | 2/27/2034 |
| Option | ◇ | — | ◇ | 2/21/2035 | |
| Option | ◇ | — | ◇ | 3/4/2032 | |
| Option | ◇ | — | ◇ | 3/4/2032 | |
| Option | ◇ | — | ◇ | 3/2/2033 | |
| Option | ◇ | — | ◇ | 3/2/2033 | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/21/2035 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | = | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/27/2034 | |
| Herriot Tabuteau | Option | ◇ | — | ◇ | 2/21/2035 |
| Option | ◇ | — | ◇ | 2/27/2034 | |
| Option | ◇ | — | ◇ | 3/2/2033 | |
| Option | ◇ | — | ◇ | 3/4/2032 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Mark Coleman Lead independent director | ◇ | ◇ | ◇ | — | — | — | ◇ |
Mark Saad | ◇ | ◇ | ◇ | — | — | — | ◇ |
Roger Jeffs | ◇ | ◇ | ◇ | — | — | — | ◇ |
Susan Mahony | ◇ | ◇ | ◇ | — | — | — | ◇ |
Herriot Tabuteau served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options and RSUs.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Alector, Inc. ALEC
- Allogene Therapeutics, Inc. ALLO
- Apellis Pharmaceuticals, Inc. APLS
- BridgeBio Pharma, Inc. BBIO
- Collegium Pharmaceutical, Inc. COLL
- Revance Therapeutics, Inc RVNC
- Zai Lab Limited ZLAB
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 5, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 6, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 7, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 2, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 3, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 4, 2021 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Axsome Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Axsome Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
222 figures on this page: 215 cited to the filing that reported them, 7 calculated from figures it prints.
215 cited to the filing
7 calculated from the filing
Documents cited
- 0001193125-26-264043Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-26-1776102025 Grants of Plan-Based Awards · Director Compensation · Outstanding Equity Awards as of December 31, 2025 · Summary Compensation Table
- 0000950170-25-083793Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-24-071960Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-23-027059Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-22-011269Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-21-031994Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Axsome Therapeutics executive compensation, FY2025.” https://intel.velarion.ai/comp/AXSM (accessed 2026).
Short form: data: Velarion
The paid brief for Axsome Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Axsome Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Axsome Therapeutics discloses
The companies named in AXSM's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}